Sign up to save your podcasts
Or
Share Managing comorbidities in diabetes – NASH and MAFLD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Managing comorbidities in diabetes – NASH and MAFLD
Non-alcoholic steatohepatitis (NASH) is a growing concern for all patients with metabolic disease. This liver disease is an advanced form of fatty liver disease, recently renamed to metabolic-associated fatty liver disease (MAFLD), which is present in up to 90% of people with obesity, type 2 diabetes or metabolic syndrome. As 20% of people with MAFLD will progress to NASH, this is an important subset of patients, and a common comorbidity to consider.
Join Professor William Alazawi for a summary of how to identify and manage NASH among people with diabetes.
References:
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
View all episodes
By Liberum IME
5
11 ratings
Non-alcoholic steatohepatitis (NASH) is a growing concern for all patients with metabolic disease. This liver disease is an advanced form of fatty liver disease, recently renamed to metabolic-associated fatty liver disease (MAFLD), which is present in up to 90% of people with obesity, type 2 diabetes or metabolic syndrome. As 20% of people with MAFLD will progress to NASH, this is an important subset of patients, and a common comorbidity to consider.
Join Professor William Alazawi for a summary of how to identify and manage NASH among people with diabetes.
References:
This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.